

Name of Journal: *World Journal of Transplantation*

Manuscript NO: 56893

Manuscript Type: OPINION REVIEW

Lenvatinib as first-line for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?

Piñero *F et al.* Lenvatinib in recurrent HCC

Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva

Match Overview

1	Internet 115 words crawled on 07-Aug-2020 www.elsevier.es	4%
2	Crossref 30 words Federico Piñero, Mario Tanno, Gabriel Aballay Soterias, Matias Tisi Baña et al. "Argentinian clinical practice guideline for sur ..."	1%
3	Internet 21 words crawled on 14-May-2018 www.oncotarget.com	1%
4	Internet 13 words crawled on 19-Nov-2017 link.springer.com	<1%
5	Internet 12 words crawled on 03-Jun-2017 linknovate.com	<1%
6	Internet 12 words crawled on 29-Apr-2019 jamanetwork.com	<1%



Lenvatinib as first-line for recurrent HCC after liver transp



ALL IMAGES VIDEOS

27,000 Results Any time

Phase I Trial of Sorafenib Following Liver Transplantation ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439789>

Subjects. Post-liver-transplant HCC patients aged 18 years or older with histologically confirmed HCC on explant were recruited. Subjects were defined as "high risk" for recurrence by being outside the Milan criteria either by radiologic criteria before transplant or pathologic criteria in the explant, by having tumors with vascular invasion, or by having poorly differentiated tumor histology.

Cited by: 7 Author: Abby B. Siegel, Anthony B. El-Khoueiry, ...
Publish Year: 2015

Search Tools

Turn off Hover Translation (关闭取词)

Locoregional Therapy and Recurrent Hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777313>

Kaplan-Meier analysis of hepatocellular carcinoma (HCC) recurrence after orthotopic liver transplantation. (A) The survival rate was significantly decreased in patients with HCC recurrence. (B-F) Recurrence risks were stratified by locoregional therapies and tumor necrosis. Log Rank Test, p<0.05 was considered as significant.

Cited by: 9 Author: Min Xu, MB Majella Doyle, Babak Banan, ...
Publish Year: 2017

Lenvatinib as first-line for recurrent hepatocellular carcinoma after li



ALL

IMAGES

VIDEOS

24,000 Results

Any time ▾

Adaptive Zoom

[Hepatocellular Carcinoma Recurrence After Liver ...](#)

<https://www.cancernetwork.com/article/...>

Mar 19, 2020 · Chok KSH. Management of **Recurrent hepatocellular carcinoma after liver transplant**. World J Hepatol. 2015;7(8):1142-1148. doi: 10.4254/wjh.v7.i8.1142. 31. Rivera L, Giap H, Miller W, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of **recurrent hepatocellular carcinoma after liver transplantation**: a case report.

Author: Alejandro Gabutti, Sherrie Bhoori, T... **Publish Year:** 2020

[Targeted therapy for hepatocellular carcinoma | Signal ...](#)

<https://www.nature.com/articles/s41392-020-00264-x>

Aug 11, 2020 · Iavarone, M. et al. Preliminary experience on safety of regorafenib **after** sorafenib failure in **recurrent hepatocellular carcinoma after liver transplantation**. Am. J. Transplant...

Author: Ao Huang, Xin-Rong Yang, Wen-Yu... **Publish Year:** 2020

[A global view of hepatocellular carcinoma: trends, risk ...](#)

<https://www.nature.com/articles/s41575-019-0186-y>

Aug 22, 2019 · Kudo, M. et al. **Lenvatinib** versus sorafenib in **first-line** treatment of **patients** with unresectable **hepatocellular carcinoma**: a randomised phase 3 non-inferiority trial. Lancet 391 , 1163–1173 (2018).

Cited by: 193 **Author:** Ju Dong Yang, Pierre Hainaut, Gregory ...

Publish Year: 2019

[Systemic therapies for hepatocellular carcinoma: a recap ...](#)

<https://hrjournal.net/article/view/2501>

Lenvatinib versus sorafenib in **first-line** treatment of **patients** with unresectable **hepatocellular carcinoma**: a randomised phase III non-inferiority trial. Lancet 2018;391:1163-73. DOI: 56. Markowitz JN, Fancher KM. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy



61,100 Results Any time ▾

Hepatocellular Carcinoma Recurrence After Liver ...

<https://www.cancernetwork.com/view/hepatocellular...> ▾

Mar 19, 2020 · Chok KSH. Management of **Recurrent hepatocellular carcinoma after liver transplant**. World J Hepatol. 2015;7(8):1142-1148. doi: 10.4254/wjh.v7.i8.1142. 31. Rivera L, Giap H, Miller W, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of **recurrent hepatocellular carcinoma after liver transplantation**: a case report.

Impact of treatment modalities on patients with recurrent ...

<https://www.sciencedirect.com/science/article/pii/S1499387220301168>

Aug 01, 2020 · Introduction. **Hepatocellular carcinoma** (HCC) is the sixth most common **cancer** worldwide and the fourth major cause of **cancer**-related death .Because of the high prevalence of hepatitis B virus (HBV) infection and **liver** cirrhosis, 55% of the new cases and deaths occur in China .As a potentially curative treatment for **liver** cirrhosis and **cancer**, **liver transplantation** (LT) is widely ...

Cited by: 1 **Author:** Zhe Yang, Shuo Wang, Xin-Yao Tian, Qin...

Publish Year: 2020

Locoregional Therapy and Recurrent Hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777313>

Kaplan-Meier analysis of **hepatocellular carcinoma** (HCC) **recurrence after** orthotopic **liver transplantation**. (A) The survival rate was significantly decreased in **patients** with HCC **recurrence**. (B–F) **Recurrence** risks were stratified by locoregional therapies and tumor necrosis. Log Rank Test, $p < 0.05$ was considered as significant.

Cited by: 11 **Author:** Min Xu, MB Majella Doyle, Babak Banan,...

Publish Year: 2017

Systemic therapies for hepatocellular carcinoma: a recap ...

<https://hrjournal.net/article/view/2501> ▾

Lenvatinib versus sorafenib in **first-line** treatment of **patients** with unresectable **hepatocellular carcinoma**: a randomised phase III non-inferiority trial. Lancet 2018;391:1163-73. DOI; 56. Markowitz JN, Fancher KM. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy 2018;38:357-69. DOI PubMed; 57.

Author: Petros Giovanis, Manuela De Bona, F... **Publish Year:** 2018